ALL

For adults (18+ years) with
relapsed or refractory B-cell precursor
acute lymphoblastic leukemia (ALL)

MCL

For adult patients
with relapsed or refractory
mantle cell lymphoma (MCL)

References: 1. TECARTUS® (brexucabtagene autoleucel). Prescribing information. Kite Pharma, Inc; 2021. 2. U.S. FDA approves Kite’s TECARTUS™, the first and only CAR T treatment for relapsed or refractory mantle cell lymphoma. News release. Kite, a Gilead Company; July 24, 2020. Accessed January 7, 2021. https://www.businesswire.com/news/home/20200724005428/en/U.S.-FDA-Approves-Kite%E2%80%99s-Tecartus%E2%84%A2-CAR-Treatment 3. U.S. FDA approves Kite's Tecartus® as the first and only CAR T for adults with relapsed or refractory B-cell acute lymphoblastic leukemia. News release. Kite, a Gilead Company; October 1, 2021. Accessed October 1, 2021. https://www.businesswire.com/news/home/20211001005719/en/ 4. KYMRIAH® (tisagenlecleucel). Prescribing information. Novartis Pharmaceuticals Corporation; 2021. 5. Shah BD, Ghobadi A, Oluwole OO, et al. KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study. Lancet. 2021;398(10299):491-502.